AR017266A1 - Compuesto azabenzoimidazolico, composicion farmaceutica que lo comprende, metodo para sintetizarlo, metodo para modular la funcion de una serina/treoninaproteina-quinasa con dicho compuesto, metodo para identificar compuestos que modulan tal funcion y uso del mismo para preparar una composicion farm - Google Patents

Compuesto azabenzoimidazolico, composicion farmaceutica que lo comprende, metodo para sintetizarlo, metodo para modular la funcion de una serina/treoninaproteina-quinasa con dicho compuesto, metodo para identificar compuestos que modulan tal funcion y uso del mismo para preparar una composicion farm

Info

Publication number
AR017266A1
AR017266A1 ARP980104793A ARP980104793A AR017266A1 AR 017266 A1 AR017266 A1 AR 017266A1 AR P980104793 A ARP980104793 A AR P980104793A AR P980104793 A ARP980104793 A AR P980104793A AR 017266 A1 AR017266 A1 AR 017266A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
homocyclic
independently selected
modulate
Prior art date
Application number
ARP980104793A
Other languages
English (en)
Original Assignee
Zentgraf Matthias
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentgraf Matthias filed Critical Zentgraf Matthias
Publication of AR017266A1 publication Critical patent/AR017266A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un compuesto de azabenzoimidazolico que posee una estructura descripta por las formulas I, II o III, en donde (a) R1, R2, R3, y R4 se seleccionanindependientemente del grupo que integran: (i) hidrogeno; (ii) alquilo saturado o no saturado; (iii) NX2X3, donde X2 y X3 se seleccionan independientemente delgrupo que integran: hidrogeno, alquilo saturado o no saturado, y anillos homocíclicos o heterocíclicos; (iv) halogeno o trihalometilo; (v) una cetona deformula -CO-X4, donde X4 se selecciona del grupo que conforman hidrogeno, alquilo,y anillos homocíclicos o heterocíclicos; (vi) un ácido carboxílico de formula-(X5)n-COOH o éster de formula -(Xb)n-COO-X7 donde X5, X6 y X7 se seleccionan independientemente del grupo que integran alquilo o anillos homocíclicos oheterocíclicos, y donde n vale 0 o 1; (vii) un alcohol de formula (X8)n-OH o un grupo alcoxi de formula -(X8)n-O-X9, donde X8 y X9 se eligenindependientemente del grupo que conforman hidrogeno, alquilo saturado o no saturado, y anillos homocíclicos o heterocíclicos, donde el anillo se sustituyeopcionalmente con uno o varios sustituyentes elegidos del grupo que integran alquilo, alcoxi, halogeno, trihalometilo, carboxilato, nitro y éster, y donde nvale 0 o 1; (viii) una amida deformula -NHCOX10, donde X10 se selecciona del grupo que integran alquilo, hidroxilo, y anillos homocíclicos o heterocíclicos, ydonde el anillo se sustituye opcionalmente con uno o varios sustituyentes independientemente seleccionados del grupo que conforman alquilo, alcoxi, halogeno,trihalometilo, carboxilato, nitro y éster; (ix) -SO2NX33X12, donde X33 y X32 se seleccionan del grupo que integran hidrogeno, alquilo y anillos homocíclicos oheterocíclicos; (x) un anillo homocíclico o heterocíclicosustituido con uno, dos o tres sustituyentes seleccionados independientemente del grupo que conformanalquilo, alcoxi, halogeno, trihalometilo, caboxilato, nitro y éster; (xi) un aldehído de formula -CO-H; y (xii) una sulfona de formula -SO2-X13, donde X13 seelige del grupo que conforman alquilo saturado o no saturado y anillos homocíclicos o heterocíclicos; (b) Z1 y Z2 se seleccionan independientemente del grupo
ARP980104793A 1997-09-26 1998-09-25 Compuesto azabenzoimidazolico, composicion farmaceutica que lo comprende, metodo para sintetizarlo, metodo para modular la funcion de una serina/treoninaproteina-quinasa con dicho compuesto, metodo para identificar compuestos que modulan tal funcion y uso del mismo para preparar una composicion farm AR017266A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6014597P 1997-09-26 1997-09-26

Publications (1)

Publication Number Publication Date
AR017266A1 true AR017266A1 (es) 2001-09-05

Family

ID=22027657

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104793A AR017266A1 (es) 1997-09-26 1998-09-25 Compuesto azabenzoimidazolico, composicion farmaceutica que lo comprende, metodo para sintetizarlo, metodo para modular la funcion de una serina/treoninaproteina-quinasa con dicho compuesto, metodo para identificar compuestos que modulan tal funcion y uso del mismo para preparar una composicion farm

Country Status (28)

Country Link
US (2) US6093728A (es)
EP (1) EP1017384B1 (es)
JP (1) JP2001517699A (es)
KR (1) KR100547929B1 (es)
CN (1) CN1167420C (es)
AR (1) AR017266A1 (es)
AT (1) ATE281834T1 (es)
AU (1) AU748849B2 (es)
BG (1) BG64784B1 (es)
BR (1) BR9812682A (es)
CA (1) CA2305370C (es)
DE (1) DE69827516T2 (es)
DK (1) DK1017384T3 (es)
ES (1) ES2230719T3 (es)
HK (1) HK1032206A1 (es)
HU (1) HUP0004024A3 (es)
IL (4) IL135109A0 (es)
NO (1) NO325663B1 (es)
NZ (2) NZ503432A (es)
PL (1) PL191618B1 (es)
PT (1) PT1017384E (es)
RU (1) RU2230553C2 (es)
SK (1) SK285357B6 (es)
TR (1) TR200001546T2 (es)
TW (1) TW581815B (es)
UA (1) UA72448C2 (es)
WO (1) WO1999016438A1 (es)
ZA (1) ZA988797B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142236A1 (en) * 1994-05-31 2006-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6384049B1 (en) * 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
JP2004528304A (ja) * 2001-03-12 2004-09-16 アバニール・ファーマシューティカルズ ＩｇＥを調節し、細胞増殖を阻害するためのベンゾイミダゾール化合物
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
WO2005013950A2 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
EP1962892A4 (en) * 2005-11-22 2011-10-12 Univ South Florida INHIBITION OF CELL PROLIFERATION
CA2649994A1 (en) 2006-04-26 2007-11-08 Cancer Research Technology Limited Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
EP2078016B1 (en) * 2006-10-19 2012-02-01 Signal Pharmaceuticals LLC Heteroaryl compounds, compositions thereof, and methods of treatment therewith
EP2839839B1 (en) * 2007-02-28 2018-01-17 Yeda Research And Development Company Limited Nuclear targeting sequences
JP5352476B2 (ja) 2007-06-05 2013-11-27 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8344135B2 (en) 2007-08-29 2013-01-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
DK2229391T3 (da) 2007-12-19 2014-10-13 Cancer Res Inst Royal Pyrido[2,3-B]pyrazin-8-substituerede forbindelser og deres anvendelse
GB0807609D0 (en) 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20100184851A1 (en) * 2008-08-29 2010-07-22 University Of South Florida Inhibition of cell proliferation
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
JP2012197231A (ja) * 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
NZ599549A (en) 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
PL2531502T3 (pl) 2010-02-01 2014-08-29 Cancer Research Tech Ltd 1-(5-tert-Butylo-2-fenylo-2H-pirazol-3-ilo)-3-[2-fluoro-4-(1-metylo-2-okso-2,3-dihydro-1H-imidazo[4,5-b]pirydyn-7-yloksy)-fenylo]-mocznik i związki pokrewne oraz ich zastosowanie w terapii
WO2013059396A2 (en) 2011-10-19 2013-04-25 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
CN104093398B (zh) 2011-12-02 2017-03-15 西格诺药品有限公司 7‑(6‑(2‑羟基丙烷‑2‑基)吡啶‑3‑基)‑1‑((反式)‑4‑甲氧基环己基)‑3,4‑二氢吡嗪并[2,3‑b]吡嗪‑2(1h)‑酮、其固体形式的药物组合物及其使用方法
BR112014020786A2 (pt) 2012-02-24 2020-10-27 Signal Pharmaceuticals, Llc método para tratamento de câncer de pulmão, método para alcançar um critério de avaliação de resposta em tumores sólidos, método para aumento da sobrevivência
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP2945636B1 (en) 2013-01-16 2017-06-28 Signal Pharmaceuticals, LLC Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
EP2970277B1 (en) 2013-03-15 2021-07-28 Knopp Biosciences LLC Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
WO2014172432A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
WO2014172426A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
BR112015026021A2 (pt) 2013-04-17 2017-07-25 Signal Pharm Llc terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
TW201527300A (zh) 2013-04-17 2015-07-16 Signal Pharm Llc 關於１－乙基－７－（２－甲基－６－（１Ｈ－１，２，４－三唑－３－基）吡啶－３－基）－３，４－二氫吡并［２，３－ｂ］吡－２（１Ｈ）－酮之醫藥調配物、方法、固態型式及使用方法
JP6382949B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法
MX2015014589A (es) 2013-04-17 2016-04-25 Signal Pharm Llc Tratamiento de cancer con dihidropirazino-pirazinas.
EA029072B1 (ru) 2013-04-17 2018-02-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Комбинированная терапия, включающая соединение дигидропиразинопиразина и антагонист рецептора андрогена для лечения рака простаты
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
US9695402B2 (en) 2013-09-17 2017-07-04 Yeda Research And Development Co. Ltd. ERK-derived peptides and uses thereof
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
US9737535B2 (en) 2014-04-16 2017-08-22 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
FI3572405T3 (fi) 2014-09-12 2023-09-22 Knopp Biosciences Llc Benzoimidatsol-1,2-yyli amidit kv7 kanavan aktivaattoreina
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3590045A (en) * 1969-09-25 1971-06-29 Smith Kline French Lab Certain substituted imidazo (4,5-b)pyridines
BE788065A (fr) 1971-08-26 1973-02-26 Degussa Nouvelles aza-benzimidazoles et procede pour leur preparation
SE422799B (sv) 1975-05-28 1982-03-29 Merck & Co Inc Analogiforfarande for framstellning av 1,3-dihydroimidazo (4,5-b)pyridin-2-oner
ES473201A1 (es) * 1977-09-26 1979-03-16 Degussa Procedimiento para la preparacion de 7-azabencimidazoles
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE69105495T2 (de) * 1990-04-02 1995-04-06 Pfizer Benzylphosphonsäure-tyrosinkinaseinhibitoren.
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
WO1992020642A1 (en) * 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
JPH06503095A (ja) * 1991-05-29 1994-04-07 ファイザー・インコーポレーテッド 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
CZ283965B6 (cs) * 1992-08-06 1998-07-15 Warner-Lambert Company 2-thioindolové, 2-indolinthionové a polysulfidové sloučeniny, 2-selenoindolové, 2-indolinselenonové a selenidové sloučeniny a farmaceutické prostředky na jejich bázi
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5582995A (en) 1993-06-11 1996-12-10 The General Hospital Corporation Methods of screening for compounds which inhibit the direct binding of Ras to Raf
US5645982A (en) * 1993-08-19 1997-07-08 Systemix, Inc. Method for screening potential therapeutically effective antiviral agents
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease

Also Published As

Publication number Publication date
IL158649A (en) 2006-12-10
CA2305370C (en) 2006-11-28
ATE281834T1 (de) 2004-11-15
BR9812682A (pt) 2000-08-22
PT1017384E (pt) 2005-03-31
AU748849B2 (en) 2002-06-13
AU9578198A (en) 1999-04-23
HUP0004024A2 (hu) 2001-04-28
DE69827516D1 (de) 2004-12-16
CA2305370A1 (en) 1999-04-08
IL135109A (en) 2007-07-04
NO325663B1 (no) 2008-07-07
US6855723B2 (en) 2005-02-15
NZ517808A (en) 2003-07-25
NO20001555L (no) 2000-03-24
DE69827516T2 (de) 2005-12-01
SK4152000A3 (en) 2002-02-05
IL135109A0 (en) 2001-05-20
UA72448C2 (en) 2005-03-15
KR100547929B1 (ko) 2006-02-02
NO20001555D0 (no) 2000-03-24
ZA988797B (en) 1999-12-02
US6093728A (en) 2000-07-25
BG64784B1 (bg) 2006-04-28
WO1999016438A1 (en) 1999-04-08
PL191618B1 (pl) 2006-06-30
PL339744A1 (en) 2001-01-02
CN1167420C (zh) 2004-09-22
RU2230553C2 (ru) 2004-06-20
IL158649A0 (en) 2004-05-12
HK1032206A1 (en) 2001-07-13
EP1017384A1 (en) 2000-07-12
TR200001546T2 (tr) 2000-10-23
DK1017384T3 (da) 2005-01-31
KR20010015623A (ko) 2001-02-26
ES2230719T3 (es) 2005-05-01
CN1278172A (zh) 2000-12-27
EP1017384B1 (en) 2004-11-10
TW581815B (en) 2004-04-01
NZ503432A (en) 2002-11-26
JP2001517699A (ja) 2001-10-09
US20030181480A1 (en) 2003-09-25
SK285357B6 (sk) 2006-11-03
HUP0004024A3 (en) 2001-10-29
BG104356A (en) 2000-12-29

Similar Documents

Publication Publication Date Title
AR017266A1 (es) Compuesto azabenzoimidazolico, composicion farmaceutica que lo comprende, metodo para sintetizarlo, metodo para modular la funcion de una serina/treoninaproteina-quinasa con dicho compuesto, metodo para identificar compuestos que modulan tal funcion y uso del mismo para preparar una composicion farm
AR013542A1 (es) Compuesto 5-azaquinoxalinico, composicion farmaceutica que lo comprende, metodo para sintetizarlo, metodo para modular la funcion de una serina/treoninaproteina-quinasa con dicho compuesto, metodo para identificar compuestos que modulan tal funcion y uso del mismo para preparar una composicion farma
UA74391C2 (uk) Арил- або гетероарилконденсовані імідазоли як антизапальні і анальгетичні агенти
AR005053A1 (es) Compuestos de difenilhexano, un procedimiento para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos, y procedmientos para la manufactura de medicamentos para inhibir la infeccion de hiv
BR9910971A (pt) Composto, processos para a preparação de um composto e para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto, e, composição farmacêutica
HUP9700358A2 (hu) Új oxazolidinonszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
CO5601011A2 (es) Derivados de 3-ciclil-5-(anillo de 5 miembros que contiene nitrogeno) metil-oxazolidinona y su uso como agentes antibacterianos
EA200401613A1 (ru) Лекарственное средство для лечения рака
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
HUP0000591A2 (hu) Fémproteáz inhibitor hatású piperazin-, morfolin- és tiomorfolin-származékok és alkalmazásuk gyógyszerkészítmények előállítására
MX9102209A (es) Derivados de acido hidroxamico y n-hidroxiurea novedosos y su uso.
SE9302080D0 (sv) New compounds
EA200401615A1 (ru) ИНГИБИТОРЫ АКТИВАЦИИ NF-kB
DE60021873D1 (de) Zubereitung zur prophylaxe oder behandlung der demenz-erkrankung enthaltend ein hydroxyzimtsäurederivat oder einen extrakt einer pflanze der gattung angelica, der diese säure enthält.
AR016175A1 (es) Compuestos derivados del acido dihidroxihexanoico, su uso para la preparacion de medicamentos y composiciones de los mismos.
ES2115220T3 (es) Nuevo uso de compuestos bis-heterociclicos como agentes antiinflamatorios y composiciones farmaceuticas de los mismos.
DK0652874T3 (da) 2-heterocycliske-5-hydroxy-1,3-pyrimidiner der er nyttige som antiinflammatoriske midler
YU13299A (sh) Postupak i intermedijari za dobijanje hromanolnih derivata
AR019256A1 (es) Utilizacion de derivados tetraciclo[6-6-2-0(2.27).0(9.14)] hexadeca-2(7), 3, 5, 9(14), 10,12-hexaeno, para la preparacion de preparados farmaceuticos conaccion inhibitoria de la fosfolipasa, los referidos derivados y preparado farmaceutico que contiene por lo menos a uno de dichos derivados
ES2183492T3 (es) Nuevos derivados de nitrono,su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
DE60139409D1 (de) Pharmazeutische zusammensetzungen die ein dibenzocyclooctanlignanderivat enthalten zur vorbeugung und behandlung neurodegenerativer erkrankungen
AR036028A1 (es) Compuesto de pirimidina, procedimiento para su preparacion, composiciones farmaceuticas formuladas con dichos compuestos y uso de los compuestos en la preparacion de las composiciones mencionadas
DK0891346T3 (da) Dihydrobenzofuranforbindelser, der er nyttige som antiinflammatoriske midler
ES476408A1 (es) Un procedimiento de preparacion de derivados de 2,4-tiazoli-dindiona.
DK0832078T3 (da) N-hydroxyurinstoffer som anti-inflammatoriske midler

Legal Events

Date Code Title Description
FB Suspension of granting procedure